TABLE 3.

Positivity rate of MAC-ELISA using wt-VLP and FP-VLP from ZIKV and DENV-2/3 among four different groups of serum panels

Serum panel (no. of serum samples)	No. positive/total no. tested (% positive)a
	ZIKV-wt-VLP	ZIKV-FP-VLP	DENV2/3-wt-VLPb	DENV2/3-FP-VLP
ZIKV (21)	21/21 (100)	21/21 (100)	20/21 (95.2)	20/21 (95.2)
Acute (23)	16/23 (69.6)	18/23 (78.3)	22/23 (95.7)	22/23 (95.7)
Convalescent (19)	18/19 (94.7)	19/19 (100)	19/19 (100)	18/19 (94.7)
WNV (56)	2/56 (3.6)	0/56 (0)	NA	NA
DENV (44)	28/44 (63.6)*	17/44 (38.6)*	42/44 (95.5)	38/44 (86.4)
Acute (40)	17/40 (42.5)*	13/40 (32.5)*	22/40 (55.0)	15/40 (37.5)
Convalescent (42)	23/42 (54.8)*	9/42 (21.4)*	40/42 (95.2)	38/42 (90.5)
Other (76)c	0/76 (0)	0/76 (0)	0/76 (0)	0/76 (0)

^a*, P < 0.05, with statistical significance.

^bThe cutoff for DENV-2/3 VLP is based on our previous publications (13, 37).

^cThis was a control serum panel, including 10 yellow fever IgG-positive specimens (17D vaccinated), two St. Louis encephalitis virus (SLEV) IgM-positive specimens, 10 chikungunya virus IgM-positive specimens, 8 nonarboviral patients, and 46 normal human serum specimens from the CDC blood bank collection.